The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 901–1,000 of 1,029
Ubiquitination and activation of a Rab GTPase promoted by a β2-Adrenergic Receptor/HACE1 complex
Lachance, V., Degrandmaison, J., Marois, S., Robitaille, M., Génier, S., Nadeau, S., Angers, S., & Parent, J. (2013) · Journal of Cell Science · doi:10.1242/jcs.132944 · Cited by 50
“highlights their importance in the treatment of disease (Hopkins and Groom, 2002).”
BackgroundBarneh, F., Jafari, M., & Mirzaie, M. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv094 · Cited by 53
Hughes, D. J., Tiede, C., Penswick, N., Tang, A. A.-S., Trinh, C. H., Mandal, U., Zajac, K. Z., Gaule, T. G., Howell, G. J., Edwards, T. A., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aaj2005 · Cited by 52
“Mutational screens rely on changing key amino acids and determining the ability of the protein tomaintain function (2), but this can result in truncated ormisfolded proteins.”
Lempiäinen, H., Brænne, I., Michoel, T., Tragante, V., Vilne, B., Webb, T. R., Kyriakou, T., Eichner, J., Zeng, L., Willenborg, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20721-6 · Cited by 53
Survey of Similarity-Based Prediction of Drug-Protein Interactions
Wang, C., & Kurgan, L. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190808154841 · Cited by 52
Basciu, A., Malloci, G., Pietrucci, F., Bonvin, A. M. J. J., & Vargiu, A. V. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00730 · Cited by 55
Predicting synthetic lethal interactions using conserved patterns in protein interaction networks
Benstead-Hume, G., Chen, X., Hopkins, S. R., Lane, K. A., Downs, J. A., & Pearl, F. M. G. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006888 · Cited by 55
“U2OS-derived control and PBRM1-deficient cell lines [64] were cultured in Dulbecco DMEM supplemented with 10% FBS, glutamine and Penicilin/Streptomycin.”
MethodMining Natural Products for Macrocycles to Drug Difficult Targets
Begnini, F., Poongavanam, V., Over, B., Castaldo, M., Geschwindner, S., Johansson, P., Tyagi, M., Tyrchan, C., Wissler, L., Sjö, P., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01569 · Cited by 50
Oncology studies using siRNA libraries: the dawn of RNAi-based genomics
Sachse, C., & Echeverri, C. J. (2004) · Oncogene · doi:10.1038/sj.onc.1208072 · Cited by 50
“…data sets by focusing the screens on ‘highpriority genes’, known from expression profiling data, for example, to be expressed in commonly occurring tumours, or genes linked to key pathways through in silico or proteomics data, or simply, genes predicted to be ‘druggable’ (Hopkins and Groom, 2002).”
BackgroundNgamcherdtrakul, W., Bejan, D. S., Cruz‐Muñoz, W., Reda, M. M., Zaidan, H. Y., Siriwon, N., Marshall, S. K., Wang, R., Nelson, M. A., Rehwaldt, J. P. C., et al. (2022) · Small · doi:10.1002/smll.202107550 · Cited by 58
Hudson, B. D., Smith, N. J., & Milligan, G. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00006-3 · Cited by 53
Heeres, J. T., & Hergenrother, P. J. (2011) · Chem. Soc. Rev. · doi:10.1039/b923660k · Cited by 49
GPCR NaVa database: natural variants in human G protein-coupled receptors
Kazius, J., Wurdinger, K., van Iterson, M., Kok, J. N., Bäck, T., & IJzerman, A. P. (2007) · Human Mutation · doi:10.1002/humu.20638 · Cited by 49
“In sharp contrast, numerous nonolfactory GPCRs regulate bodily functions and are key targets for therapeutic intervention: roughly 30% of the marketed drugs target GPCRs [Hopkins and Groom, 2002].”
BackgroundDruggable Targets and Targeted Drugs: Enhancing the Development of New Therapeutics
Billingsley, M. L. (2008) · Pharmacology · doi:10.1159/000157624 · Cited by 52
“Current best estimates are that of the 25,000 or so human genes, only 400–1,000 genes are currently drug targets [”
BackgroundLigand specificity, privileged substructures and protein druggability from fragment-based screening
Barelier, S., & Krimm, I. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.02.020 · Cited by 51
“Protein druggability assessment by FBS The concept of protein druggability [16], proposed in 2002 by Hopkins [17], is generally [18] viewed as a crucial point in drug discovery [19,20].”
MethodSpot 14: A Marker of Aggressive Breast Cancer and a Potential Therapeutic Target
Kinlaw, W. B., Quinn, J. L., Wells, W. A., Roser-Jones, C., & Moncur, J. T. (2006) · Endocrinology · doi:10.1210/en.2006-0463 · Cited by 49
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
Yurugi, H., Marini, F., Weber, C., David, K. A., Zhao, Q., Binder, H., Désaubry, L., & Rajalingam, K. (2017) · Oncogene · doi:10.1038/onc.2017.93 · Cited by 52
Bioluminescence imaging of G protein-coupled receptor activation in living mice
Kono, M., Conlon, E. G., Lux, S. Y., Yanagida, K., Hla, T., & Proia, R. L. (2017) · Nature Communications · doi:10.1038/s41467-017-01340-7 · Cited by 50
Yin, J., Chen, X., Wang, C.-C., Zhao, Y., & Sun, Y. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00384 · Cited by 49
ROSENKILDE, M. M., Smit, M. J., & Waldhoer, M. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707660 · Cited by 57
“Rhodopsin-like 7TM receptors: structure and function Despite the fact that around 50% of all drugs on the market target 7TM receptors (Drews, 2000; Hopkins and Groom, 2002), we still know very little about the structure of these receptors.”
BackgroundSmall Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins
Turner, E. M., Blazer, L. L., Neubig, R. R., & Husbands, S. M. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200263y · Cited by 49
Druggability of human disease genes
Sakharkar, M. K., Sakharkar, K. R., & Pervaiz, S. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.018 · Cited by 52
Form follows function: Shape analysis of protein cavities for receptor‐based drug design
Weisel, M., Proschak, E., Kriegl, J. M., & Schneider, G. (2009) · PROTEOMICS · doi:10.1002/pmic.200800092 · Cited by 51
“It has been estimated that the effective number of such targets that can be exploited by the pharmaceutical industry comprises only several hundreds of potential targets [1].”
BackgroundRokosz, L. L., Beasley, J. R., Carroll, C. D., Lin, T. H., Zhao, J., Appell, K. C., & Webb, M. L. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.7.883 · Cited by 51
“Despite the fact that the kinome accounts for 22% of the druggable genome [1] , only seven approved drugs are inhibitors of kinases.”
BackgroundSignal Transduction Therapy with Rationally Designed Kinase Inhibitors
Kéri, G., Őrfi, L., Erös, D., Hegymegi-Barakonyi, B., Szántai-Kis, C., Horvath, Z., Wáczek, F., Jeno, M., Szabadkai, I., Pató, J., et al. (2006) · Current Signal Transduction Therapy · doi:10.2174/157436206775269190 · Cited by 50
McMahon, R. M., Premkumar, L., & Martin, J. L. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.01.013 · Cited by 49
Pfleger, K. D. G., & Eidne, K. A. (2003) · Pituitary · doi:10.1023/b:pitu.0000011175.41760.5d · Cited by 49
“Furthermore, they are estimated to account for 25–50% of current drug targets [6,7].”
BackgroundGenomics and the second golden era of cancer drug development
Workman, P. (2005) · Molecular BioSystems · doi:10.1039/b501751n · Cited by 53
Grigoriadis, D. E., Hoare, S. R. J., Lechner, S. M., Slee, D. H., & Williams, J. A. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.149 · Cited by 52
“Ion channels appear to be represented by 400 genes in the human genome (Venter et al, 2001) and are currently the targets for approximately 7% of the current marketed drugs (Hopkins and Groom, 2002).”
BackgroundA functional SNP in EDG2 increases susceptibility to knee osteoarthritis in Japanese
Mototani, H., Iida, A., Nakajima, M., Furuichi, T., Miyamoto, Y., Tsunoda, T., Sudo, A., Kotani, A., Uchida, A., Ozaki, K., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn069 · Cited by 49
“We selected 64 GPCRs expressed in the cartilage based on GeneChip (Affymetrix) analysis using total cartilage RNAs from eight OA and eight normal individuals described previously (16).”
BackgroundInfluentialDisulfide Click Reaction for Stapling of S‐terminal Peptides
Yu, Q., Bai, L., & Jiang, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202314379 · Cited by 53
Fernando, I. P. S., & Wu, J. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.104896 · Cited by 56
Oxysterol‐EBI2 signaling in immune regulation and viral infection
Daugvilaite, V., Arfelt, K. N., Benned‐Jensen, T., Sailer, A. W., & ROSENKILDE, M. M. (2014) · European Journal of Immunology · doi:10.1002/eji.201444493 · Cited by 50
Retinal Conformation Governs pKaof Protonated Schiff Base in Rhodopsin Activation
Zhu, S., Brown, M. F., & Feller, S. E. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4002986 · Cited by 52
Donoghue, P. M., Staunton, L., Mullen, E., Manning, G., & Ohlendieck, K. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.01.014 · Cited by 48
“Integral proteins are both of fundamental biological importance and represent crucial therapeutic targets [35], giving central importance to the identification of their role in aging.”
BackgroundPerspectives on new strategies for the identification and development of insecticide targets
Swale, D. R. (2019) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2019.07.001 · Cited by 49
The Resurrection of Phenotypic Drug Discovery
Childers, W. E., Elokely, K. M., & Abou-Gharbia, M. A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00006 · Cited by 55
Li, Z., Lim, S. L., Tao, Y., Li, X., Xie, Y., Yang, C., Zhang, Z., Jiang, Y., Zhang, X., Cao, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574525 · Cited by 51
“However, targeting the Myc family protein, including N-Myc, is still challenging due to the lack of pockets that could be targeted directly with small molecules (5).”
BackgroundMass spectrometry and the cellular surfaceome
Pauwels, J., Fijałkowska, D., Eyckerman, S., & Gevaert, K. (2021) · Mass Spectrometry Reviews · doi:10.1002/mas.21690 · Cited by 52
Magnetic particles for enzyme immobilization: A versatile support for ligand screening
Ximenes, I. A. T., de Oliveira, P. C. O., Wegermann, C. A., & de Moraes, M. C. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.114286 · Cited by 58
Promiscuous drugs as therapeutics for chemokine receptors
Horuk, R. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000921 · Cited by 51
Zang, Q., Javed, S., Porubsky, P. R., Ullah, F., Neuenswander, B., Lushington, G. H., Basha, F. Z., Organ, M. G., & Hanson, P. R. (2012) · ACS Combinatorial Science · doi:10.1021/co200181x · Cited by 48
Capter 11 Filtering in Drug Discovery
Lipinski, C. A. (2005) · Annual reports in computational chemistry · doi:10.1016/s1574-1400(05)01011-x · Cited by 53
Golden, M. S., Cote, S. M., Sayeg, M., Zerbe, B. S., Villar, E. A., Beglov, D., Sazinsky, S. L., Georgiadis, R. M., Vajda, S., Kozakov, D., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400914z · Cited by 47
Flexible Side Chain Models Improve Enrichment Rates in In Silico Screening
Kokh, D. B., & Wenzel, W. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800217k · Cited by 47
Targeting tight junction proteins-significance for drug development
Kondoh, M., Yoshida, T., Kakutani, H., & Yagi, K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.005 · Cited by 49
Ísberg, V., Balle, T., Sander, T., Jørgensen, F. S., & Gloriam, D. E. I. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100402f · Cited by 47
Distinct PKA and Epac compartmentalization in airway function and plasticity
Dekkers, B. G. J., Racké, K., & Schmidt, M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.006 · Cited by 50
Smith, N. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00275 · Cited by 50
Identification of potential therapeutic targets in prostate cancer through a cross‐species approach
Jurmeister, S., Ramos‐Montoya, A., Sandi, C., Pértega‐Gomes, N., Wadhwa, K., Lamb, A. D. G., Dunning, M., Attig, J., Carroll, J. S., Fryer, L. G. D., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708274 · Cited by 49
“The number of potentially druggable genes in the human genome has been estimated at ~3,000 (Hopkins & Groom, 2002).”
BackgroundHuang, R., Xia, M., Sakamuru, S., Zhao, J., Lynch, C., Zhao, T., Zhu, H., Austin, C. P., & Simeonov, A. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-22046-w · Cited by 50
Dynamics of human protein kinase Aurora A linked to drug selectivity
Pitsawong, W., Buosi, V., Otten, R., Agafonov, R. V., Zorba, A., Kern, N., Kutter, S., Kern, G., Pádua, R. A., Meniche, X., et al. (2018) · eLife · doi:10.7554/elife.36656 · Cited by 44
Chavali, S. S., Bonn, R. B., & Wedekind, J. E. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006860 · Cited by 52
“5–10% of the proteome is likely to be druggable (7, 8).”
BackgroundExploring the dark genome: implications for precision medicine
Oprea, T. I. (2019) · Mammalian Genome · doi:10.1007/s00335-019-09809-0 · Cited by 50
“The TCRD/Pharos platform is well suited to address questions about the “druggable genome,” which Hopkins and Groom defined (Hopkins and Groom 2002) as the set of protein-encoding genes that can be therapeutically modulated by orally formulated drugs, using Lipinski’s “rule of five” criteria, which…”
Systematic illumination of druggable genes in cancer genomes
Jiang, J., Yuan, J., Hu, Z., Zhang, Y., Zhang, T., Xu, M., Long, M., Fan, Y., Tanyi, J. L., Montone, K. T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110400 · Cited by 45
“To define the potentially druggable genes (PDGs), candidates from 6 comprehensive druggable gene resources (Carvalho-Silva et al., 2019; Finan et al., 2017; Hopkins and Groom, 2002; Kumar et al., 2013; Russ and Lampel, 2005; Southan et al., 2015) were integrated.”
InfluentialSystems Cell Biology Based on High‐Content Screening
Giuliano, K. A., Johnston, P. A., Gough, A., & Taylor, D. L. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)14031-8 · Cited by 50
“In addition, absolute specificity of small molecules and biologics is rarely demonstrated and ‘‘off‐target’’ effects must be understood for both efficacy and potential toxicity ( Hopkins and Groom, 2002; Yang et al., 2004).”
BackgroundStructure-Based Discovery of Potassium Channel Blockers from Natural Products
Liu, H., Li, Y., Song, M., Tan, X., Cheng, F., Zheng, S., Shen, J., Luo, X., Ji, R., Yue, J., et al. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.10.011 · Cited by 50
Σκρέτας, Γ., & Georgiou, G. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.00963-10 · Cited by 47
“From a biotechnological standpoint, membrane proteins are valuable targets for pharmaceutical discovery: it is estimated that approximately 50% of all drugs in use or under development act by modulating the function of this class of proteins (18).”
BackgroundThe Response of Lactococcus lactis to Membrane Protein Production
Marreddy, R. K. R., Pinto, J. P. C., Wolters, J. C., Geertsma, E. R., Fusetti, F., Permentier, H. P., Kuipers, O. P., Kok, J., & Poolman, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024060 · Cited by 48
“available pharmaceutical drugs target membrane proteins [1].”
Thomas, J. R., Liu, X., & Hergenrother, P. J. (2006) · Biochemistry · doi:10.1021/bi0607296 · Cited by 53
Functional genomics using high-throughput RNA interference
Vanhecke, D., & Janitz, M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03352-5 · Cited by 52
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 62
Biophysical Methods in Drug Discovery from Small Molecule to Pharmaceutical
Holdgate, G. A., Geschwindner, S., Breeze, A. L., Davies, G. M., Colclough, N., Temesi, D. G., & Ward, L. T. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-398-5_12 · Cited by 54
Small-molecule modulators of 14-3-3 protein–protein interactions
Ottmann, C. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.028 · Cited by 56
Differences between High- and Low-Affinity Complexes of Enzymes and Nonenzymes
Carlson, H. A., Smith, R. D., Khazanov, N. A., Kirchhoff, P. D., Dunbar, J. B., & Benson, M. L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8006504 · Cited by 46
Druggability Assessment of Protein–Protein Interfaces
Wanner, J., Fry, D. C., Peng, Z., & Roberts, J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.156 · Cited by 44
Production of GPCR and GPCR complexes for structure determination
Maeda, S., & Schertler, G. F. X. (2013) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2013.04.006 · Cited by 46
Preethi, S., Schomay, T. E., Aiello, K. A., & Alter, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121396 · Cited by 47
Systems genetics for drug target discovery
Penrod, N. M., Sallari, R. C., & Moore, J. H. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.002 · Cited by 51
“All biological macromolecules (i.e., DNA, RNA, proteins, carbohydrates and lipids) are potential drug targets, although the vast majority of drugs target proteins [1, 2].”
BackgroundYang, J., Jang, R., Zhang, Y., & Shen, H. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt440 · Cited by 48
“It has been shown that450% of current drug targets are membrane proteins (Hopkins and Groom, 2002), where the top four gene families of Food and Drug Administration-approved drugs are all membrane proteins; i.e.”
BackgroundInterrogating the druggable genome with structural informatics
Hambly, K., Danzer, J. F., Muskal, S. M., & Debe, D. A. (2006) · Molecular Diversity · doi:10.1007/s11030-006-9035-3 · Cited by 46
“[2] as functional domains which have been shown to bind compounds obeying the Lipinski Rule-of-5 criteria for drug-likeness [20].”
BackgroundMethodIntroduction: Cell-Based Assays for High-Throughput Screening
An, W. F., & Tolliday, N. J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-545-3_1 · Cited by 59
Pluskal, T., & Weng, J. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00411g · Cited by 50
The signal peptide as a new target for drug design
Lumangtad, L. A., & Bell, T. W. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127115 · Cited by 51
Machine learning based analyses on metabolic networks supports high-throughput knockout screens
Plaimas, K., Mallm, J., Oswald, M., Svara, F., Sourjik, V., Eils, R., & König, R. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-67 · Cited by 56
“In particular, metabolic enzymes have been successfully targeted by specific drugs to inhibit essential processes of pathogenic organisms in the human host [1].”
BackgroundFrom Five- to Six-Membered Rings: 3,4-Diarylquinolinone as Lead for Novel p38MAP Kinase Inhibitors
Peifer, C., Kinkel, K., Abadleh, M. M., Schollmeyer, D., & Laufer, S. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061097o · Cited by 48
Differential Membrane Proteomics Using 18O-Labeling To Identify Biomarkers for Cholangiocarcinoma
Kristiansen, T. Z., Gowda, H., Grønborg, M., Maitra, A., & Pandey, A. (2008) · Journal of Proteome Research · doi:10.1021/pr800215n · Cited by 50
Σκρέτας, Γ., Meligova, A. K., Villalonga‐Barber, C., Mitsiou, D. J., Alexis, Μ. N., Micha‐Screttas, M., Steele, B. R., Screttas, C. G., & Wood, D. W. (2007) · Journal of the American Chemical Society · doi:10.1021/ja067754j · Cited by 47
Karhemo, P., Ravela, S., Laakso, M., Ritamo, I., Tatti, O., Mäkinen, S., Goodison, S., Stenman, U., Hölttä, E., Hautaniemi, S., et al. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.07.009 · Cited by 55
“Currently, two-thirds of the protein-based drug targets are located at the cell surface while cell surface proteins represent only about 22% of all proteins in the human genome [6,7].”
BackgroundSolution NMR Spectroscopy of the Human Vasopressin V2 Receptor, A G Protein-Coupled Receptor
Tian, C., BREYER, R. M., Kim, H. J., Karra, M., Friedman, D. B., Karpay, A., & Sanders, C. R. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051161b · Cited by 46
Xu, J., Wang, P., Yang, H. J., Zhou, J., Li, Y., Li, X., Xue, W., Yu, C., Tian, Y., & Zhu, F. (2016) · BioMed Research International · doi:10.1155/2016/2509385 · Cited by 47
“Therefore, a comparison of systemprofileswould help to discover key factors defining the druggabilities of established targets [19–22].”
Natural Products Drug Discovery
Appendino, G., Fontana, G., & Pollastro, F. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00064-2 · Cited by 56
Möller, G., Deluca, D., Gege, C., Rosinus, A., Kowalik, D., Peters, O., Droescher, P., Elger, W. A. G., Adamski, J., & Hillisch, A. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.113 · Cited by 45
The challenges of developing novel antiparasitic drugs
Woods, D. J., & Williams, T. M. (2007) · Invertebrate Neuroscience · doi:10.1007/s10158-007-0055-1 · Cited by 45
“Discovery scientists have found that certain proteins are more amenable to binding ‘‘rule of 5’’-compliant molecules than others and named this attribute ‘‘druggability’’ (Hopkins and Groom 2002).”
BackgroundEdwards, A., Wachter, F., Lammert, M., Huhn, A. J., Luccarelli, J., Bird, G. H., & Walensky, L. D. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00214 · Cited by 50
Perspectives towards antiviral drug discovery against Ebola virus
Mirza, M. U., Vanmeert, M., Ali, A., Iman, K., Froeyen, M., & Idrees, M. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25357 · Cited by 49
PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling
Nawrotek, A., Benabdi, S., Niyomchon, S., Kryszke, M.-H., Ginestier, C., Cañeque, T., Tepshi, L., Mariani, A., St.Onge, R. P., Giaever, G. N., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0228-3 · Cited by 46
How to Illuminate the Druggable Genome Using Pharos
Sheils, T., Mathias, S. L., Siramshetty, V. B., Bocci, G., Bologa, C. G., Yang, J. J., Waller, A., Southall, N., Nguyen, D., & Oprea, T. I. (2020) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.92 · Cited by 45
“The druggable genome was defined as “the subset of the (cid:2) 30,000 genes in the human genome that express proteins potentially able to bind drug-like molecules” (Hopkins & Groom, 2002).”
BackgroundTarget Analysis: A Priori Assessment of Druggability
Hopkins, A. L., & Groom, C. R. (2003) · Springer eBooks · doi:10.1007/978-3-662-05314-0_2 · Cited by 45
Self-citationStructure-based Ligand Design and the Promise Held for Antiprotozoan Drug Discovery
Hunter, W. N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800072200 · Cited by 46
Cao, R., He, Q., Zhou, J., He, Q., Liu, Z., Wang, X., Chen, P., Xie, J., & Liang, S. (2008) · Journal of Proteome Research · doi:10.1021/pr070411f · Cited by 47
Identifying novel genes contributing to asthma pathogenesis
Holloway, J. W., & Koppelman, G. H. (2007) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e328013d51b · Cited by 45
Are MAP Kinases Drug Targets? Yes, but Difficult Ones
Margutti, S., & Laufer, S. (2007) · ChemMedChem · doi:10.1002/cmdc.200600271 · Cited by 46
Kinases control of regulated cell death revealing druggable targets for Parkinson’s disease
Mansour, H. M., Mohamed, A. F., El-Khatib, A. S., & Khattab, M. M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101841 · Cited by 51
Cantacessi, C., Campbell, B. E., & Gasser, R. B. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.016 · Cited by 46
Krausz, E. (2007) · Molecular BioSystems · doi:10.1039/b616187c · Cited by 44
Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development
Duran‐Frigola, M., Mosca, R., & Aloy, P. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.03.004 · Cited by 51
Liu, A., Tweed, J. A., & Wujcik, C. E. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.05.012 · Cited by 44
Improving human health through understanding the complex structure of glucose polymers
Gilbert, R. G., Wu, A. C., Sullivan, M. A., Sumarriva, G. E., Ersch, N., & Hasjim, J. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-7129-1 · Cited by 46
Magnani, M., Pierigè, F., & Rossi, L. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.6 · Cited by 44
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.